Catalio Capital Management
Catalio Capital Management is a venture capital firm based in New York, founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein. The firm focuses on investing in breakthrough biomedical technology companies, seeking to support innovation in this critical sector. Catalio Capital Management engages in various investment strategies, including private equity, private credit, and public equity, while employing a fundamental, bottoms-up approach to investment analysis. As a Registered Investment Adviser, the firm aims to leverage its expertise to identify and nurture promising companies in the biomedical field, contributing to advancements in healthcare and technology.
Past deals in Maryland
Sensei Biotherapeutics
Series B in 2021
Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, with an additional office in Boston, Massachusetts. Founded in 1999, the company specializes in developing precision cancer therapeutics, particularly next-generation immunotherapies. Sensei's proprietary drug discovery platform, ImmunoPhage, focuses on understanding the tumor microenvironment to create novel biologics that target tumor-specific antigens and activate both the innate and adaptive immune systems. The company is working on a range of investigational product candidates, including SNS-101, SNS-102, SNS-103, and SNS-20, which aim to address unmet needs in cancer treatment by selectively disabling immunosuppressive signals or activating immunostimulatory signals within the tumor microenvironment. Through its innovative approach and collaboration with experts in biology, immunology, and oncology, Sensei Biotherapeutics seeks to transform cancer treatment and improve outcomes for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.